Kezar Life Sciences Inc (NAS:KZR)

$ 0.7699 0.0042 (0.55%) Market Cap: 56.05 Mil Enterprise Value: -105.77 Mil PE Ratio: 0 PB Ratio: 0.33 GF Score: 28/100

Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Kezar Life Sciences Inc at Wells Fargo Healthcare Conference Transcript
Sep 07, 2023
Kezar Life Sciences Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Kezar Life Sciences Inc R&D Day Transcript
Mar 15, 2023
Alpine Immune Sciences Inc and Kezar Life Sciences Inc at Cowen Health Care Conference- Panel Transcript
Mar 07, 2023
Kezar Life Sciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Kezar Life Sciences Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call Transcript
Jun 27, 2022
Kezar Life Sciences Inc Annual Shareholders Meeting Transcript
Jun 25, 2021
Kezar Life Sciences Inc At TMA's International Annual Patient Conference Transcript
Sep 22, 2020
Q2 2020 Kezar Life Sciences Inc Earnings Call Transcript
Aug 05, 2020

$4.72 (+1.83%)

Earnings
Kezar Life Sciences Inc At MSU: Rare Disease Day Presentation Transcript
Apr 15, 2020
Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 Transcript
Mar 05, 2020

Kezar Life Sciences Inc at Jefferies Healthcare Conference Transcript

Jun 08, 2023 / 06:00PM GMT

Release Date Price: $2.47 (-15.12%)

Transcript

Maury Raycroft

Jefferies, LLC - Analyst

My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. And I'd like to welcome the Kezar team with me today, and we're going to do a fireside chat discussion. Maybe to start off if you want to provide a one-minute intro to Kezar.

John Fowler

Kezar Life Sciences, Inc. - CEO, Co-Founder

Yeah, hi, everybody. Thanks for joining us today. My name is John Fowler. I'm Co-Founder and CEO of Kezar. Founded the company in 2015 and actually met Maury in 2018. We've been working together for five years now.

We're based in the San Francisco Bay area, went public in 2018, and we actually have two drugs in the clinic at this time. Our lead asset is a small molecule called zetomipzomib -- we'll refer to it as zeto today -- is a selective immunoproteasome inhibitor. We have seen some amazing results to date, treating patients with both lupus and lupus nephritis, and we're currently enrolling a Phase 2b in lupus nephritis and also a Phase 2 in autoimmune hepatitis.

Our other clinical asset is a

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.